scholarly journals Correlation between cytologic features and histologic grades in cutaneous and subcutaneous soft tissue sarcomas in dogs—A pilot study

2021 ◽  
Author(s):  
Sonia Sanchez‐Redondo ◽  
Cassia H. Z. Hare ◽  
Fernando Constantino‐Casas ◽  
Tim L. Williams
Keyword(s):  
Pilot Study ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas

Perioperative high-dose-rate brachytherapy in soft tissue sarcomas of the extremity and superficial trunk in adults: Initial results of a pilot study

Brachytherapy ◽  
2005 ◽  
Vol 4 (4) ◽  
pp. 264-270 ◽  
Author(s):  
Rafael Martínez-Monge ◽  
Mikel San Julián ◽  
Santiago Amillo ◽  
Mauricio Cambeiro ◽  
Leire Arbea ◽  
...  
Keyword(s):  
Pilot Study ◽  
Soft Tissue ◽  
Dose Rate ◽  
Soft Tissue Sarcomas ◽  
High Dose Rate ◽  
High Dose ◽  
High Dose Rate Brachytherapy ◽  
Initial Results

scholarly journals Towards applying NMR relaxometry as a diagnostic tool for bone and soft tissue sarcomas: a pilot study

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Elzbieta Masiewicz ◽  
George P. Ashcroft ◽  
David Boddie ◽  
Sinclair R. Dundas ◽  
Danuta Kruk ◽  
...  
Keyword(s):  
Pilot Study ◽  
Soft Tissue ◽  
Diagnostic Tool ◽  
Soft Tissue Sarcomas ◽  
Nmr Relaxometry

High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.

1997 ◽  
Vol 15 (6) ◽  
pp. 2378-2384 ◽  
Author(s):  
S R Patel ◽  
S Vadhan-Raj ◽  
N Papadopolous ◽  
C Plager ◽  
M A Burgess ◽  
...  
Keyword(s):  
Pilot Study ◽  
Soft Tissue ◽  
Continuous Infusion ◽  
Phase Ii ◽  
Dose Response ◽  
Overall Response Rate ◽  
Response Rate ◽  
Soft Tissue Sarcomas ◽  
High Dose ◽  
Grade 3

PURPOSE To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas. PATIENTS AND METHODS Between July 1991 and February 1994, 74 patients with sarcomas (37 bone and 37 soft tissue) were treated on two simultaneous phase II studies that evaluated HDI given as a continuous infusion over 74 hours. G-CSF was started on day 5 at 5 microg/kg/d until recovery of granulocyte count. Additionally, between March 1993 and March 1994, 15 similar patients with previously treated bone or soft tissue sarcomas were treated on a pilot study in which the same total dose of ifosfamide was administered by a bolus schedule, along with mesna and G-CSF. Patients were treated until maximal response, and where possible, surgical resection of gross disease was performed. RESULTS Seventy-two patients from the phase II study using continuous infusion are assessable for response. Four complete responses (CRs) and 17 partial responses (PRs) were noted, for an overall response rate of 29% (95% confidence interval [CI], 19% to 39%). The response rate was 40% (95% CI, 24% to 56%) for bone sarcomas and 19% (95% CI, 6% to 32%) for soft tissue sarcomas. Fourteen patients from the pilot study that used a bolus schedule are assessable for response. One CR and seven PRs were noted, for an overall response rate of 57% (95% CI, 31% to 83%) and a response rate of 45% for soft tissue sarcomas. Two patients developed grade 3 to 4 renal toxicity, three developed grade 3 CNS toxicity, one had possible grade 3 cardiac toxicity, and two developed severe painful peripheral neuropathy. There were no treatment-related deaths. CONCLUSION HDI at 14 g/m2 with mesna and G-CSF is an active salvage regimen for patients with bone and soft tissue sarcomas. There is a definite positive dose-response curve, and bolus administration appears to be more active than continuous infusion.

Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics

2014 ◽  
Vol 45 (8) ◽  
pp. 1563-1571 ◽  
Author(s):  
George Jour ◽  
John D. Scarborough ◽  
Robin L. Jones ◽  
Elizabeth Loggers ◽  
Seth M. Pollack ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Pilot Study ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Molecular Profiling ◽  
Next Generation ◽  
Generation Sequencing ◽  
Precision Therapeutics

scholarly journals Functional Outcome After Lower Extremity Soft Tissue Sarcoma Treatment: A Pilot Study Based on Translated and Culturally Adapted Measures

2018 ◽  
Vol 108 (2) ◽  
pp. 164-171
Author(s):  
G. Kask ◽  
I. Barner-Rasmussen ◽  
J. Repo ◽  
C. Blomqvist ◽  
E. Tukiainen
Keyword(s):  
Pilot Study ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Lower Extremity ◽  
Functional Outcome ◽  
Soft Tissue Sarcomas ◽  
Musculoskeletal Tumor ◽  
Musculoskeletal Tumor Society ◽  
Toronto Extremity Salvage Score ◽  
Extremity Salvage

Background and Aims: The present standard of care in treating lower extremity soft tissue sarcomas is function-sparing, limb-preserving resection and reconstruction with or without oncological therapy. The aim of this pilot study was to test the suitability and adequacy of the Finnish translations of two functional outcome questionnaires (Toronto Extremity Salvage Score and Musculoskeletal Tumor Society score) and to perform a preliminary investigation of functional outcomes of Finnish lower-limb soft tissue sarcoma patients after operative treatment. Materials and Methods: Between June 2015 and December 2015, consecutive surgically treated outpatients were asked to participate in the study. Demographic, clinical, surgical, and oncological outcome data were collected. Two functional outcome questionnaires were used (Toronto Extremity Salvage Score and Musculoskeletal Tumor Society scores). A comparative analysis is presented. Results: A total of 19 lower-limb soft tissue sarcoma patients with a mean follow-up time of 2 years and 10 months were included. All (n = 19) invited patients participated in the study. Mean age was 62.3 years. In total, 13 had high-grade sarcomas. Eight wounds were closed directly, four used skin grafts, and five required flap reconstructions. One patient required a tumor prosthesis, and one required a rotationplasty. A total of 14 patients received oncological therapy. No problems or difficulties were reported in using and completing the Finnish versions of the Toronto Extremity Salvage Score or Musculoskeletal Tumor Society questionnaires. The overall Toronto Extremity Salvage Score and Musculoskeletal Tumor Society scores were 88 and 76, respectively. Conclusion: This pilot study suggests that the Finnish versions of the Toronto Extremity Salvage Score and Musculoskeletal Tumor Society questionnaires are suitable for measuring functional outcome after lower extremity soft tissue sarcomas treatment. Functional outcomes vary from moderate to excellent.

Pilot study of a rapid etoposide-cisplatin regimen in paediatric soft tissue sarcomas

1992 ◽  
Vol 28 (2-3) ◽  
pp. 399-403 ◽  
Author(s):  
Marianne B. Phillips ◽  
C. Ross Pinkerton
Keyword(s):  
Pilot Study ◽  
Soft Tissue ◽  
Soft Tissue Sarcomas
Sign in / Sign up

Export Citation Format

Share Document